KPI-012

About Kala Pharmaceuticals

Kala Bio is a clinical-stage biotech focused on developing regenerative therapies for rare ocular surface and retinal diseases using its proprietary mesenchymal stem cell secretome (MSC-S) platform. The company executed a strategic transformation in 2022, divesting its two FDA-approved commercial products to Alcon to concentrate resources on its novel biologic pipeline. Its lead asset, KPI-012, is in Phase 2b development for persistent corneal epithelial defect (PCED), with potential in other severe surface disorders. Kala's mission is to leverage advanced science to solve serious eye diseases and change patients' lives.

About Kala Pharmaceuticals

Kala Bio is a clinical-stage biotech focused on developing regenerative therapies for rare ocular surface and retinal diseases using its proprietary mesenchymal stem cell secretome (MSC-S) platform. The company executed a strategic transformation in 2022, divesting its two FDA-approved commercial products to Alcon to concentrate resources on its novel biologic pipeline. Its lead asset, KPI-012, is in Phase 2b development for persistent corneal epithelial defect (PCED), with potential in other severe surface disorders. Kala's mission is to leverage advanced science to solve serious eye diseases and change patients' lives.

Therapeutic Areas